Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies

Cancer Science

Volumn 102, Issue 11, 2011, Pages 2051-2057

  Nakazawa, Youya ^a,b   Takagi, Satoshi ^a   Sato, Shigeo ^a   Oh hara, Tomoko ^a   Koike, Sumie ^a   Takami, Miho ^a   Arai, Hiroyuki ^b   Fujita, Naoya ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; C TYPE LECTIN LIKE RECEPTOR 2; CHIMERIC ANTIBODY; EPITOPE; LECTIN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HAG 3; MONOCLONAL ANTIBODY P2 0; NEUTRALIZING ANTIBODY; PODOPLANIN; THREONINE; THROMBOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL INTERACTION; CHO CELL; CONFORMATION; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; HAPLORHINI; HUMAN; HUMAN CELL; LUNG METASTASIS; METASTASIS INHIBITION; MOLECULAR CLONING; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEOPLASM; ANTIBODIES, NEUTRALIZING; CHO CELLS; CRICETINAE; CRICETULUS; EPITOPES; FEMALE; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASTIC CELLS, CIRCULATING; PLATELET AGGREGATION; PROTEIN CONFORMATION; RECOMBINANT FUSION PROTEINS; SPECIES SPECIFICITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054968142     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02058.x     Document Type: Article

References (32)

1. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 2005; 26: 195-200.
2. Martín-Villar E, Scholl FG, Gamallo C et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 2005; 113: 899-910.
3. Yuan P, Temam S, El-Naggar A et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006; 107: 563-9.
4. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006; 9: 261-72.
5. Kimura N, Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int 2005; 55: 83-6.
6. Fukunaga M. Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology 2005; 46: 396-402.
7. Kato Y, Sasagawa I, Kaneko M, Osawa M, Fujita N, Tsuruo T. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 2004; 23: 8552-6.
8. Mishima K, Kato Y, Kaneko MK et al. Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol 2006; 111: 563-8.
9. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 2006; 111: 483-8.
10. Kunita A, Kashima TG, Morishita Y et al. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 2007; 170: 1337-47.
11. Kato Y, Fujita N, Kunita A et al. Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 2003; 278: 51599-605.
12. Malik AB. Pulmonary microembolism. Physiol Rev 1983; 63: 1114-207.
13. Fidler IJ. Metastasis: quantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst 1970; 45: 773-82.
14. Philippe C, Philippe B, Fouqueray B, Perez J, Lebret M, Baud L. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol 1993; 143: 1713-23.
15. Suzuki-Inoue K, Kato Y, Inoue O et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 2007; 282: 25993-6001.
16. Christou CM, Pearce AC, Watson AA et al. Renal cells activate the platelet receptor CLEC-2 through podoplanin. Biochem J 2008; 411: 133-40.
17. Suzuki-Inoue K, Fuller GL, García A et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 2006; 107: 542-9.
18. Niwa R, Shoji-Hosaka E, Sakurada M et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64: 2127-33.
19. Kato Y, Kaneko MK, Kunita A et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 2008; 99: 54-61.
20. Ogasawara S, Kaneko MK, Price JE, Kato Y. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma 2008; 27: 259-67.
21. Kato Y, Kaneko MK, Kuno A et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 2006; 349: 1301-7.
22. Kaneko M, Kato Y, Kunita A, Fujita N, Tsuruo T, Osawa M. Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells. J Biol Chem 2004; 279: 38838-43.
23. Nakazawa Y, Sato S, Naito M et al. Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood 2008; 112: 1730-9.
24. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004; 104: 397-401.
25. Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66, 329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4: 529-35.
26. Klerk CP, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130-5.
27. Boucharaba A, Serre CM, Grès S et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004; 114: 1714-25.
28. Massberg S, Konrad I, Schürzinger K et al. Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med 2006; 203: 1221-33.
29. Jin DK, Shido K, Kopp HG et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12: 557-67.
30. Suzuki-Inoue K, Inoue O, Ding G et al. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem 2010; 285: 24494-507.
31. May F, Hagedorn I, Pleines I et al. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 2009; 114: 3464-72.
32. Uhrin P, Zaujec J, Breuss JM et al. Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood 2010; 115: 3997-4005.